KeyBanc Capital Markets Analyst Donald Hooker is currently recommending Medidata Solutions Inc (MDSO). While it is a data company, Hooker says Medidata focuses on the pharmaceutical and biopharmaceutical space.
“They are helping digitize clinical trials and observational research. They are well-funded, they have a deep product pipeline, and they are well-aligned with key trends,” Hooker says. “They have a big total addressable market and very reasonable consensus expectations on it.”
“So it’s sort of a beat-and-raise scenario, and some near-term catalyst potential for this within some different legislation that is in process of that addresses the use of information technology in clinical trials,” Hooker adds.
He is referring to the 21st Century Cures Act, which passed the House in July and is working its way through Congress to the President’s desk.
“That has helped set the stage for the health hubs and safeguards and regulations around using technology in clinical trials,” Hooker says. “That would accelerate demand for Medidata potentially over the next couple of years.”
Medidata Solutions Inc (MDSO) Sees Revenue Growth, Margin Improvement as a Provider of SaaS Clinical Tech Solutions
October 31, 2013
Medidata Solutions (MDSO) Provides Key Clinical-Research SaaS Solutions for Big Pharma
November 01, 2012
Medidata Solutions Inc (MDSO) Poised for Pricing Power
May 22, 2015
Medidata Solutions (NASDAQ:MDSO) Ready to Replace Oracle (NASDAQ:ORCL) in Clinical Trials Cloud Software
October 12, 2017
Solid Tumor Cancer Cures: Bio-Path Holdings May Hold the Key
April 16, 2019
